PD30-09: Response to Primary Chemoablation With UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial

PD30-09: Response to Primary Chemoablation With UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial

Saturday, May 4, 2024 2:20 PM to 2:30 PM · 10 min. (US/Central)
304A
Delete

Registered attendees

Max Kates
Max Kates
Director, Division of Urologic OncologyJohns Hopkins Hospital
Padraic O'Malley
Padraic O'Malley
Associate ProfessorUniversity of Florida
William Huang
William Huang
Professor of Urology (urologic oncology) and RadiologyNYU Urology Associates

Log in